The FDA approved an mRNA-based influenza vaccine mFLUSIVA for adults aged 50 years and older, with accelerated approval applying to adults aged 65 years and older.
The FDA has approved the first vaccine approved in the US for the prevention of dengue disease caused by all 4 serotypes of dengue virus in patients aged 9 through 16 years with laboratory-confirmed...
